Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Environmental health

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Environmental health. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2012-004509-29 Sponsor Protocol Number: 2012-776 Start Date*: 2015-11-03
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Antidepressant treatments during pregnancy and lactation: prediction of drug exposure through breastfeeding and evaluation of drug effect on the neonatal adaptation and the development of the youn...
    Medical condition: depression
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001281-86 Sponsor Protocol Number: CNTO888PUL2001 Start Date*: 2009-01-14
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in ...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002980-26 Sponsor Protocol Number: CACZ885A2102 Start Date*: 2004-12-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, phase II dose titration study of ACZ885 (human anti-IL-1beta monoclonal antibody) to assess the clinical efficacy, safety, pharmacokinetics and pharmacodynamics in patients with NALP...
    Medical condition: Muckle-Wells Syndrome: rare hereditary, autosomal dominant, systemic inflammatory disease, characterized by recurrent episodes of fever, arthralgia, myalgia, urticarial rash, and conjunctivitis. La...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-000967-40 Sponsor Protocol Number: AG011-MDUC-201 Start Date*: 2008-11-03
    Sponsor Name:ActoGeniX NV.
    Full Title: A Phase 2a Randomised, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderatle...
    Medical condition: Moderately Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-005086-39 Sponsor Protocol Number: BT-11-201 Start Date*: 2019-10-28
    Sponsor Name:Landos Biopharma Inc.
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis
    Medical condition: Mild to Moderate Ulcerative Colitis Inflammatory bowel disease (IBD) is an autoimmune disease of the gastrointestinal (GI) tract with unknown etiology that encompasses 2 primary clinical manifesta...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) HR (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001242-25 Sponsor Protocol Number: BBT120126032001 Start Date*: 2017-02-07
    Sponsor Name:Blueberry Therapeutics Ltd.
    Full Title: An Early Phase Development, Partly Blinded, Positive and Vehicle Controlled, Randomized, Non-inferiority Investigation of the Pharmacokinetics, Safety and Efficacy of BB2603 Cutaneous Hand-Pump Spr...
    Medical condition: Onychomycosis and associated Tinea Pedis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10043873 Tinea pedis PT
    20.0 10021881 - Infections and infestations 10030338 Onychomycosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001553-10 Sponsor Protocol Number: CACZ885A2204 Start Date*: 2007-06-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 26-week, phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (ACR50) and to determine a biomarker profile in responders to ACZ885 (anti-...
    Medical condition: Early Rheumatoid Arthritis in adults
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001060-28 Sponsor Protocol Number: 2020-001060-28 Start Date*: 2021-03-16
    Sponsor Name:Aarhus Universitet
    Full Title: Documentation of efficacy for intralymphatic allergen immunotherapy in a phase III randomized, parallel group, double blind placebo-controlled multisite field trial
    Medical condition: Allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004222-25 Sponsor Protocol Number: AB11003 Start Date*: 2013-11-26
    Sponsor Name:AB Science
    Full Title: A 12-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 4-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to placebo, in the...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SK (Prohibited by CA) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005262-35 Sponsor Protocol Number: 16401 Start Date*: 2013-07-08
    Sponsor Name:Bayer HealthCare AG
    Full Title: BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi...
    Medical condition: Clinically isolated syndrome (CIS) and multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) PT (Completed) HU (Completed) CZ (Completed) NO (Completed) AT (Completed) FI (Completed) DK (Completed) GB (Completed) ES (Completed) IT (Completed) SI (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 00:28:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA